{
    "clinical_study": {
        "@rank": "151377", 
        "arm_group": {
            "arm_group_label": "Pyrotinib", 
            "arm_group_type": "Experimental", 
            "description": "Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days."
        }, 
        "brief_summary": {
            "textblock": "Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.\n      This study is designed to evaluate the safety and tolerability of Pyrotinib in patients with\n      HER2 positive advanced breast cancer:\n\n        -  To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose\n           (MTD)\n\n        -  To determine the dose-limiting toxicity (DLT)\n\n        -  To determine the pharmacokinetic profile of Pyrotinib and its metabolites\n\n        -  To assess preliminary antitumor activity\n\n        -  To determine preliminary regimen dose for phase II study\n\n        -  To determine the relation of expression of HER-2 to the antitumor activity."
        }, 
        "brief_title": "Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged \u226518 and \u226470 years.\n\n          -  ECOG performance status of 0 to 1.\n\n          -  Life expectancy of more than 12 weeks.\n\n          -  At least one measurable lesion exsists.(RECIST 1.1)\n\n          -  Histologically or cytologic confirmed HER2 positive advanced breast cancer which\n             failed prior therapies.\n\n          -  Required laboratory values including following parameters:\n\n               -  ANC: \u2265 1.5 x 109/L\n\n               -  Platelet count: \u2265 100 x 109/L\n\n               -  Hemoglobin: \u2265 9.0 g/dL\n\n               -  Total bilirubin: \u2264 1.5 x upper limit of normal, ULN\n\n               -  ALT and AST: \u2264 1.5 x ULN\n\n               -  BUN and creatinie clearnce rate: \u2265 50 mL/min\n\n               -  LVEF: \u2265 50%\n\n               -  QTcF: < 470 ms\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Subjects with third space fluid that can not be controled by drainage or other\n             methods.\n\n          -  Steroid treatment for more than 50 days, or in need of long-term use of steroids.\n\n          -  Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal\n             absorption.\n\n          -  Less than 4 weeks from the last radiotherapy,chemotherapy\uff0csurgery\uff0chermone\n             treatment,target therapy, or less than 6 weeks from the nitrosoureas or mitomycin\n             chemotherapy.\n\n          -  Subjects with uncontrolled hypokalemia and hypomagniesemia before study entry.\n\n          -  Subjects who can not interrupt the using of the drugs that may cause QT prolongation\n             during study.\n\n          -  Subjects with intracranial lesions.\n\n          -  Treated or treating with HER2 TKIs before study entry.\n\n          -  Receiving any other antitumor therapy.\n\n          -  Less than 4 weeks from the last clinical trial.\n\n          -  Known history of hypersensitivity to pyrotinib or any of it components.\n\n          -  Ongoing infection (determined by investigator).\n\n          -  History of immunodeficiency, including HIV-positive, suffering from other acquired,\n             congenital immunodeficiency disease, or history of organ transplantation.\n\n          -  Subjects had any heart disease, including: (1) angina; (2) requiring medication or\n             clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5)\n             Any heart diseases judged by investigator as unsuitable to participate in the trial.\n\n          -  Female patients who are pregnancy, lactation or women who are of childbearing\n             potential tested positive in baseline pregnancy test.\n\n          -  Female patients of childbearing age that are reluctant to take effective\n             contraceptive measures throughout the trial period.\n\n          -  Evidence of significant medical illness that in the investigator's judgment will\n             substantially increase the risk associated with the subject's participation in and\n             completion of the study. Examples include, but are not limited to,hypertension,\n             severe diabetes, or thyroid disease.\n\n          -  Alcoholism, smoking (daily \u2265 5 roots) and other bad habits.\n\n          -  Known history of neurological or psychiatric disease, including epilepsy or dementia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937689", 
            "org_study_id": "BLTN-Ib"
        }, 
        "intervention": {
            "arm_group_label": "Pyrotinib", 
            "description": "Pyrotinib either at 80, 160, 240, 320 mg, p.o. once daily.", 
            "intervention_name": "Pyrotinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "advanced", 
            "Pyrotinib", 
            "Phase I", 
            "HER2 positive advanced breast cancer"
        ], 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "contact": {
                "email": "xubinghe@medmail.com.cn", 
                "last_name": "BingHe Xu, MD", 
                "phone": "(+86) 010-87788114"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
            }, 
            "investigator": {
                "last_name": "BingHe Xu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer", 
        "overall_contact": {
            "email": "xubinghe@medmail.com.cn", 
            "last_name": "BingHe Xu, MD", 
            "phone": "(+86) 010-87788114"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one subject out of three experiences has a dose-limiting toxicity (DLT) upon completing one treatment cycle.", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Objective response rate (ORR).", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Pyrotinib pharmacokinetic parameter: Cmax.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Pyrotinib pharmacokinetic parameter: Tmax.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Pyrotinib pharmacokinetic parameter: t1/2.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Pyrotinib pharmacokinetic parameter: AUC.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}